MGX Stock Forecast: Metagenomi Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Metagenomi Therapeutics, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 33 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Metagenomi Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (84): The share count has been shrinking and the company is not leaning on new borrowing.
Momentum (13): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MGX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MGX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | Wells Fargo | Maintains | Overweight | $9.00 → $7.00 |
| 7 July 2026 | Chardan Capital | Maintains | Buy | $7.00 → $5.00 |
| 12 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 19 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 14 Aug 2025 | Wells Fargo | Maintains | Overweight | — |
| 15 May 2025 | Chardan Capital | Maintains | Buy | — |
| 14 May 2025 | Wells Fargo | Maintains | Overweight | — |
| 3 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Mar 2025 | Wells Fargo | Maintains | Overweight | — |
| 10 Dec 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 21 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Nov 2024 | Chardan Capital | Maintains | Buy | — |
| 15 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Sept 2024 | Chardan Capital | Maintains | Buy | — |
| 21 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Aug 2024 | Chardan Capital | Maintains | Buy | — |
| 15 Aug 2024 | BMO Capital | Maintains | Outperform | — |
| 15 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MGX.
This page is one stock. Monday covers all of them.
MGX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MGX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Metagenomi Therapeutics, Inc. returned −62.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MGX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 3.0×
- Price / book
- 0.2×
- EV / EBITDA
- —
Cheaper than 36% of US stocks
Cheaper than 93% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −69.4%
- Return on assets
- −30.8%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Metagenomi Therapeutics, Inc. has a market value of $21.4M.
Revenue in the twelve months to 30 June 2026: $13.6M. The latest quarter shrank 103.0% year on year.
Net income over the same four quarters: −$93.5M, a −689.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$85.8M.
Metagenomi Therapeutics, Inc. employs 107 people — $127K of revenue per employee.
Data provided by Twelve Data
MGX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MGX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Metagenomi Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MGX
What is the MGX stock price forecast for 2026-2027?
The median 12-month analyst price target for Metagenomi Therapeutics, Inc. is $7, with estimates ranging from $5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MGX stock a buy right now?
Of the 5 analysts covering Metagenomi Therapeutics, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Metagenomi Therapeutics, Inc. 33 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MGX?
As at 21 Nov 2026, Metagenomi Therapeutics, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Issuance (84 of 100).
Will MGX stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $7, and Ticker Nerd's factor model ranks Metagenomi Therapeutics, Inc. 33 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MGX stock forecast for 2030?
No analyst covering Metagenomi Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $9 over the next 12 months.
How has MGX stock performed over the past year?
Metagenomi Therapeutics, Inc. returned -62.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Metagenomi Therapeutics, Inc. do?
Metagenomi Therapeutics, Inc. is a precision genetic medicines company focused on in vivo genome editing for the development of curative therapies. The company uses a proprietary metagenomics-derived toolbox to discover and engineer genome-editing systems, including nucleases, base editors, and gene-integration technologies.
About Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc. is a precision genetic medicines company focused on in vivo genome editing for the development of curative therapies. The company uses a proprietary metagenomics-derived toolbox to discover and engineer genome-editing systems, including nucleases, base editors, and gene-integration technologies. Its platform is designed to support precise DNA changes across a wide range of genetic targets, with current work centered on therapeutic programs for serious inherited conditions such as hemophilia and other genetic diseases. Metagenomi Therapeutics also collaborates with partners in biotechnology and pharmaceutical research to expand the potential uses of its editing technologies. Headquartered in Emeryville, California, Metagenomi Therapeutics, Inc. plays a role in the growing field of next-generation genetic medicine, where genome editing is being developed as a foundational approach to treating disease at its source.
CEO Dr. Jian Irish M.B.A., Ph.D. · 107 employees · United States · https://metagenomi.co